Oral Progestagens and Breast Cancer Risk
Author Information
Author(s): Alban Fabre, Anne Fournier, Sophie Mesrine, Jean Desreux, Alain Gompel, Marie-Claude Boutron-Ruault, Francois Clavel-Chapelon
Primary Institution: INSERM (Institut National de la Santé et de la Recherche Médicale)
Hypothesis
Does the use of progestagen-only treatments before menopause increase the risk of breast cancer in women over 40?
Conclusion
The study suggests that prolonged use of progestagens after the age of 40 may be associated with an increased risk of breast cancer.
Supporting Evidence
- The study included 73,664 women and identified 2,390 cases of invasive breast cancer during follow-up.
- Current use of progestagens for longer than 4.5 years was significantly associated with an increased risk of breast cancer.
- No significant association was found between ever-use of progestagens and breast cancer risk overall.
Takeaway
This study looked at whether taking certain hormones called progestagens before menopause can lead to breast cancer in older women. It found that using them for a long time might increase the risk.
Methodology
The study analyzed data from the French E3N cohort, focusing on women over 40 who used progestagens, tracking their breast cancer diagnoses over time.
Potential Biases
Self-reported data on progestagen use may lead to misclassification, but this is expected to be non-differential between cases and non-cases.
Limitations
Details on treatment dosage and frequency were not recorded, which limited the analysis of risk associated with different usage patterns.
Participant Demographics
Women aged 40-64 years from the MGEN health insurance scheme in France.
Statistical Information
P-Value
0.012
Confidence Interval
1.03–2.00
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website